The Relationship between Demographic Indicators and Mortality Rate of Covid-19 Disease Comparatively and Retrospectively in Different Waves of Covid-19 Disease in Iran

Abstract

Coronavirus disease-19 (COVID-19) is a novel emerging infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In this study, we aimed to examine the relationship between demographic indicators and mortality rates in Covid-19 disease in different Covid-19 waves in Iran. In this retrospective cross-sectional study, the study population consisted of 9874 patients of Covid-19 admitted to Hazrat Rasoul Akram Hospital of Tehran, from the beginning of the disease to the end of the fifth wave. Demographic variables such as age and sex as well as clinical variables such as hospitalization date and mortality rate were collected and evaluated. The analysis was performed using SPSS software version 26. The mean age of 9874 participants was 58.9 ± 17.0 years. In this study 5510 (55.8%) of patients were male. 1762 (17.8%) patients died. The fifth wave had the highest number of patients (31.1%) and the trend in the number of patients was increasing from wave second to fifth. However, the percentage of death was lower in waves fourth (14.5%) and fifth (15.3%). The mean age of deceased patients was significantly greater than alive patients (69.25 ± 14.60 vs. 56.76 ± 16.75, P=0.0001). The frequency of male deaths was significantly higher than female deaths (P=0.0001). The results of the present study indicate that the frequency of mortality in recent waves, despite a significant increase in hospitalization, has been decreased. It can also be said that mortality increases with age as well as male gender, and males are more prone to death due to covid-19 disease with age.

Keywords

• Coronavirus disease-19 (COVID-19)
• Mortality Rate
• Iran

References

1. 1. (WHO) WHO. Novel Coronavirus (2019-nCoV), situation report-1 2020 [Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4.
2. 2. World Health Organization (WHO). WHO Director-General's Opening Remarks at the media Briefing on COVID-19 2020 [Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
3. 3. Liu J, Liao X, Qian S, Yuan J, Wang F, Liu Y, et al. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis. 2020;26(6):1320-3.
4. 4. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-207.
5. 5. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577-82.
6. 6. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10).
7. 7. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. Treasure Island (FL)2022.
8. 8. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759-65.

9. 9. Coopersmith CM, Antonelli M, Bauer SR, Deutschman CS, Evans LE, Ferrer R, et al. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Crit Care Med. 2021;49(4):598-622.
10. 10. COVID C, Team R, COVID C, Team R, COVID C, Team R, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. Morbidity and mortality weekly report. 2020;69(12):343.
11. 11. Zali A, Gholamzadeh S, Mohammadi G, Azizmohammad Looha M, Akrami F, Zarean E, et al. Baseline Characteristics and Associated Factors of Mortality in COVID-19 Patients; an Analysis of 16000 Cases in Tehran, Iran. Arch Acad Emerg Med. 2020;8(1):e70.
12. 12. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21(1):855.
13. 13. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;23(5):1416-24.
14. 14. Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, Janani M, Sepandi M. Case fatality rate of COVID-19: a systematic review and meta-analysis. J Prev Med Hyg. 2021;62(2):E311-E20.
15. 15. Nikpouraghdam M, Jalali Farahani A, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol. 2020;127:104378.
16. 16. Azarbakhsh H, Jokari K, Moftakhar L, Ghelichi Ghojogh M, Karimyan A, Salmanzadeh S, et al. Epidemiological characteristics of patients with COVID-19 in Southwest of Iran from February 19 to June 20, 2020. Med J Islam Repub Iran. 2021;35:116.
17. 17. Emami A, Javanmardi F, Akbari A, Moghadami M, Bakhtiari H, Falahati F, et al. Characteristics of deceased patients with CoVID-19 after the first peak of the epidemic in Fars province, Iran. Infect Ecol Epidemiol. 2020;10(1):1781330.
18. 18. Rahmanian F, Hatami N, Haghbeen M, Raoufi R, Abbasi AR, Shakeri H, et al. Gender Differences in COVID-19 Deceased Cases in Jahrom City, South of Iran. Bull Emerg Trauma. 2021;9(2):80-5.
19. 19. Khosravi Shadmani F, Amanollahi A, Zali A, Najafi F, Karami M, Moradi G, et al. Description of Epidemiological Features, Symptoms and Mortality of the Patients with COVID-19 in Some Provinces of Iran. Arch Iran Med. 2021;24(10):733-40.
20. 20. Barek MA, Aziz MA, Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases. Heliyon. 2020;6(12):e05684.